Analysts estimate that CureVac will report an earnings per share (EPS) of $-0.09. Investors in CureVac are eagerly awaiting ...

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

CureVac (CVAC) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase 1 clinical ...

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where CureVac (NASDAQ:CVAC) stands against other best German ...

Curevac NV announced that the FDA has cleared its IND application for a phase I clinical study of CVHNLC in patients with ...

The firm will evaluate CVHNLC in combination with Keytruda as a first-line and first-line maintenance treatment in NSCLC.

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...

CureVac (CVAC) announced that the European Patent Office has confirmed the validity of the company’s European patent EP 3 708 668 B1 subject to ...

Novo Nordisk may miss sales expectations; federal judge fines Johnson & Johnson $1.64 billion in marketing case; CureVac mRNA ...

In this article, we are going to take a look at where CureVac (NASDAQ:CVAC) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued weakness.